ZBIO

Zenas BioPharma, Inc. (ZBIO) | Rumor.io

Zenas BioPharma

ZBIO

Attention (50-day avg)0%

Attention rank (50-day avg)#3,043

Bullish sentiment (50-day avg)100%

Price to earnings ratio1.63

Market capitalization1.8B

Earnings per share-9.64

Dividend yield (TTM)0.03%

Revenue (annual)10M

Net income (annual)-377.7M

Social

What share of all stock conversation is about ZBIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

May 19

Zenas BioPharma's ($ZBIO) CEO, Leon O. Moulder Jr., made his first recorded insider purchase, buying 60,000 shares at $16.88 for $1.0M, increasing his holdings by 162.5%.
The company will present results from its Phase 3 INDIGO trial of obexelimab in IgG4-related disease at the EULAR 2026 Congress, which may impact the stock's performance.
The CEO's buy is a notable vote of confidence in the company, with some analysts suggesting that the purchase could be a sign of a potential bounce in the stock's price.

Generated by AI

Sentiment

Of the messages about ZBIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	73.23% -14.77
Bearish	—	—	—	26.77% +14.77

Bullish· Jan 22

Mainz Biomed N.V. is pushing innovation in a field with 20+ years of limited screening progress, potentially leading to significant advancements.
The company is experiencing strong buying interest, with volume surging by up to 60% and price climbing consistently.
Mainz Biomed N.V. is showing no signs of slowing, with volume up by up to 55% and price increasing towards new levels, indicating sustained momentum.

Bearish· Jan 6

$ZBIO's stock has crashed by 52%, with insiders and institutions scooping up shares, suggesting a potential rebound.
Morgan Stanley has cut its rating on $ZBIO to Equal-Weight, with a price target of $19, and the stock is experiencing heavy relative selling and crowded short pressure.
$ZBIO's top drug has missed expectations in an immune disease study, causing its shares to plummet, and the company's management team has been accused of burying the potential miss in its 8-k filing.

Generated by AI

Topics

Of the messages about ZBIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	52.53%
Technical Analysis	—	0%	0%	6.26%
Analysts	—	0%	0%	31.97%
Earnings	—	0%	0%	0.15%
Controversies	—	0%	0%	0.2%
Macro	—	0%	0%	8.89%

Jan 23

Zenas BioPharma, Inc. (ZBIO) may benefit from the cancellation of NextNRG, Inc.'s (NXXT) ATM deal, reducing dilution and potentially driving up the stock price.
NextNRG, Inc.'s (NXXT) termination of its $60M deal with ThinkEquity is seen as a positive for ZBIO, as it eliminates dilution and may lead to stock price growth.
Zenas BioPharma, Inc. (ZBIO) CEO Moulder has purchased $1.63m in stock, indicating confidence in the company's prospects.

Generated by AI

Community

Of the messages about ZBIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	17.65%	19.23%	16.19%
Newcomers	0%	82.35%	80.77%	83.81%

Mar 27

Zenas BioPharma is simultaneously offering $200 million in convertible senior notes due 2032 and 5 million shares of common stock at $20 each, with closing expected on March 31, 2026.
The stock price of Zenas BioPharma has dropped 19% to $18.01 after announcing the offering, with key levels to watch including the new offering price and the stock's recent doubling in value.
The offering is a combination of debt and equity, with $200 million in 2.50% convertible notes due 2032 and $100 million in equity, with net proceeds of approximately $287.5 million.

Generated by AI

Zenas BioPharma (NasdaqGS:ZBIO) filed shelf registrations totaling more than US$240 million, according to recent regulatory disclosures. The filings include a broad shelf registration for potential future securities offerings across multiple instruments. A separate portion of the shelf is earmarked for an employee stock ownership plan related offering. The new shelf registrations and ESOP related shelf tell only part of the Zenas BioPharma story for investors to weigh. Our analysis turns up...

7d agoYahoo Finance

Zenas BioPharma to present obexelimab IgG4-RD trial data

8d agoInvesting.com

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on September 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase

11d agoYahoo! Finance Canada

Zenas BioPharma at H.C. Wainwright conference: pipeline nears key tests

13d agoInvesting.com

Zenas BioPharma at Morgan Stanley conference: cash, pipeline and obexelimab

15d agoInvesting.com

Also Discussed

Investors talking about ZBIO also mention

#	Name	Attention
1	Alumis Inc.ALMS	0%0
2	GH Research PLCGHRS	0%0
3	Rezolute Inc.RZLT	0%+0
4	Vor Biopharma Inc.VOR	0%new
5	Janux Therapeutics, Inc.JANX	0%0
6	Legend Biotech Corporation ADRLEGN	0%+0
7	Banner CorpBANR	0%0
8	Scinai Immunotherapeutics Ltd. American Depositary SharesSCNI	0%new
9	Cheetah Net Supply Chain Service Inc.CTNT	0.02%-0.01
10	Structure Therapeutics Inc. American Depositary SharesGPCR	0%new

Zenas BioPharma, Inc.

Healthcare
Biotechnology

Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of transformative therapies for autoimmune diseases. The company focuses on advancing innovative immunology-based treatments, with a strong commitment to addressing diseases characterized by significant unmet medical needs. Zenas BioPharma's pipeline features lead candidates such as obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, and orelabrutinib, a highly selective Bruton’s Tyrosine Kinase (BTK) inhibitor in Phase 3 development for multiple sclerosis and other autoimmune indications. The firm's portfolio also includes other monoclonal antibodies and immunomodulators under investigation for disorders like immunoglobulin G4-related disease and systemic lupus erythematosus. Guided by values emphasizing innovation, urgency, and patient impact, Zenas BioPharma operates with the aim of bringing novel treatment options to patients, their families, and caregivers, ultimately seeking to improve quality of life and redefine therapeutic possibilities in the autoimmune sector.

Website

Location

852 Winter Street

Waltham, MA, 02451

United States

Social

What share of all stock conversation is about ZBIO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

May 19

Zenas BioPharma's ($ZBIO) CEO, Leon O. Moulder Jr., made his first recorded insider purchase, buying 60,000 shares at $16.88 for $1.0M, increasing his holdings by 162.5%.
The company will present results from its Phase 3 INDIGO trial of obexelimab in IgG4-related disease at the EULAR 2026 Congress, which may impact the stock's performance.
The CEO's buy is a notable vote of confidence in the company, with some analysts suggesting that the purchase could be a sign of a potential bounce in the stock's price.

Generated by AI

Sentiment

Of the messages about ZBIO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	73.23% -14.77
Bearish	—	—	—	26.77% +14.77

Bullish· Jan 22

Mainz Biomed N.V. is pushing innovation in a field with 20+ years of limited screening progress, potentially leading to significant advancements.
The company is experiencing strong buying interest, with volume surging by up to 60% and price climbing consistently.
Mainz Biomed N.V. is showing no signs of slowing, with volume up by up to 55% and price increasing towards new levels, indicating sustained momentum.

Bearish· Jan 6

$ZBIO's stock has crashed by 52%, with insiders and institutions scooping up shares, suggesting a potential rebound.
Morgan Stanley has cut its rating on $ZBIO to Equal-Weight, with a price target of $19, and the stock is experiencing heavy relative selling and crowded short pressure.
$ZBIO's top drug has missed expectations in an immune disease study, causing its shares to plummet, and the company's management team has been accused of burying the potential miss in its 8-k filing.

Generated by AI

Topics

Of the messages about ZBIO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	52.53%
Technical Analysis	—	0%	0%	6.26%
Analysts	—	0%	0%	31.97%
Earnings	—	0%	0%	0.15%
Controversies	—	0%	0%	0.2%
Macro	—	0%	0%	8.89%

Jan 23

Zenas BioPharma, Inc. (ZBIO) may benefit from the cancellation of NextNRG, Inc.'s (NXXT) ATM deal, reducing dilution and potentially driving up the stock price.
NextNRG, Inc.'s (NXXT) termination of its $60M deal with ThinkEquity is seen as a positive for ZBIO, as it eliminates dilution and may lead to stock price growth.
Zenas BioPharma, Inc. (ZBIO) CEO Moulder has purchased $1.63m in stock, indicating confidence in the company's prospects.

Generated by AI

Community

Of the messages about ZBIO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	17.65%	19.23%	16.19%
Newcomers	0%	82.35%	80.77%	83.81%

Mar 27

Zenas BioPharma is simultaneously offering $200 million in convertible senior notes due 2032 and 5 million shares of common stock at $20 each, with closing expected on March 31, 2026.
The stock price of Zenas BioPharma has dropped 19% to $18.01 after announcing the offering, with key levels to watch including the new offering price and the stock's recent doubling in value.
The offering is a combination of debt and equity, with $200 million in 2.50% convertible notes due 2032 and $100 million in equity, with net proceeds of approximately $287.5 million.

Generated by AI

Zenas BioPharma

Social

May 19

Sentiment

Bullish· Jan 22

Bearish· Jan 6

Topics

Jan 23

Community

Mar 27

News

Can Zenas BioPharma’s (ZBIO) Clinical Pipeline Justify Its Heavy Cash Burn?

Why Is Zenas BioPharma (ZBIO) Filing More Than $240 Million In Shelves?

Zenas BioPharma to present obexelimab IgG4-RD trial data

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma at H.C. Wainwright conference: pipeline nears key tests

Zenas BioPharma at Morgan Stanley conference: cash, pipeline and obexelimab

Also Discussed

Zenas BioPharma, Inc.

Company Information

Location

News

Can Zenas BioPharma’s (ZBIO) Clinical Pipeline Justify Its Heavy Cash Burn?

Why Is Zenas BioPharma (ZBIO) Filing More Than $240 Million In Shelves?

Zenas BioPharma to present obexelimab IgG4-RD trial data

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma at H.C. Wainwright conference: pipeline nears key tests

Zenas BioPharma at Morgan Stanley conference: cash, pipeline and obexelimab

Also Discussed

Social

May 19

Sentiment

Bullish· Jan 22

Bearish· Jan 6

Topics

Jan 23

Community

Mar 27